| [1] |
World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017.
|
| [2] |
Sagwa EL, Mantel-Teeuwisse AK, Ruswa NC . Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study. J Pharm Policy Pract, 2014,7(1):14.
doi: 10.1186/2052-3211-7-14
URL
|
| [3] |
Bhushan B, Chander R, Kajal NC , et al. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab. Indian J Tuberc, 2014,61(4):318-324.
URL
pmid: 25675695
|
| [4] |
Dela AI, Tank NKD, Singh AP , et al. Adverse rug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study. Lung India, 2017,34(6):522-526.
doi: 10.4103/0970-2113.217569
URL
|
| [5] |
Zhang Y, Wu S, Xia Y , et al. Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study. Med Sci Monit, 2017,23:2348-2356.
doi: 10.12659/MSM.904682
URL
|
| [6] |
Schnippel K, Firnhaber C, Berhanu R , et al. Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother, 2017,72(7):1871-1879.
doi: 10.1093/jac/dkx107
URL
|
| [7] |
Bloss E, Kuksa L, Holtz TH , et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000—2004. Int J Tuberc Lung Dis, 2010,14(3):275-281.
URL
pmid: 20132617
|
| [8] |
中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 抗结核药所致药物性肝损伤诊断与处理专家建议. 中华结核和呼吸杂志, 2013,36(10):732-736.
doi: 10.3760/cma.j.issn.1001-0939.2013.10.007
URL
|
| [9] |
中国防痨协会. 耐药结核病化学治疗指南(2015年). 中国防痨杂志, 2015,37(5):421-469.
doi: 10.3969/j.issn.1000-6621.2015.05.001
URL
|
| [10] |
Muñoz-Torrico M, Caminero-Luna J, Migliori GB , et al. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis. Arch Bronconeumol(Article in English, Spanish), 2017,53(5):245-250.
doi: 10.1016/j.arbr.2016.10.003
URL
pmid: 28089216
|
| [11] |
Mo P, Zhu Q, Teter C , et al. Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV,tuberculosis, and epatitis virus. Int J Infect Dis, 2014,28:95-100.
doi: 10.1016/j.ijid.2014.06.020
URL
|
| [12] |
雷建平, 吴雪琼, 张文宏 . 抗结核药物所致肝损伤相关危险因素及临床处置对策. 中国防痨杂志, 2013,35(11):858-864.
|
| [13] |
Shin SS, Hyson AM, Castañeda C , et al. Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2003,7(4):347-353.
doi: 10.1080/01902140390116580
URL
pmid: 12729340
|
| [14] |
Skinner MH, Blaschke TF . Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet, 1995,28(2):115-125.
doi: 10.2165/00003088-199528020-00003
URL
|
| [15] |
Healan AM, Griffiss JM, Proskin HM , et al. Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers. Antimicrob Agents Chemother, 2017, 62(1): pii:e00855-17.
|
| [16] |
Doherty AM, Kelly J, McDonald C, et al. A review of the interplay between tuberculosis and mental health. Gen Hosp Psychiatry, 2013,35(4):398-406.
doi: 10.1016/S0924-9338(13)77395-4
URL
pmid: 23660587
|
| [17] |
Arbex MA, Varella Mde C, Siqueira HR , et al. Antituberculosis drugs: drug interactions,adverse effects, and use in pecial situations. Part 2: second line drugs. J Bras Pneumol(Article in English, Portuguese), 2010,36(5):641-656.
|
| [18] |
谭守勇, 黎燕琼 . 加强耐多药结核病患者的药物不良反应管理. 结核病与肺部健康杂志, 2015,4(4):213-214.
doi: 10.3969/j.issn.2095-3755.2015.04.001
URL
|
)
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
